Galapagos Closes Inpharmatica Acquisition | GenomeWeb
NEW YORK (GenomeWeb News) - Galapagos today said it has issued a final tranche of 113,378 shares to close its acquisition of informatics firm Inpharmatica.
 
Galapagos announced in December that it was acquiring the UK-based company in a share exchange over three tranches worth as much as €19.1 million ($25.4 million).
 
Galapagos plans to fold Inpharmatica into its drug discovery services business, BioFocus DPI.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.